Introduction
Although not the same as tuberculosis, Mycobacterium kansasii (M. kansasii) is a form of bacteria that can cause similar lung issues. While it behaves somewhat like tuberculosis (infectious disease affecting lungs), it is not the same and is hence referred to as "non-tuberculosis." It creates a pigment that causes it to turn yellow when exposed to light. This bacteria was initially discovered by scientists in 1953. Under a microscope, the substance appears as thick, rectangular rods longer than those caused by tuberculosis bacteria. Like tuberculosis, M. kansasii primarily affects the top region of the lungs and causes a chronic illness that forms holes in the lung tissue. While the number of tuberculosis cases has decreased, the number of illnesses caused by bacteria such as M. kansasii has increased. Though some research indicates that M. kansasii infections may be declining in frequency, the frequency of these infections is unclear.
What Are the Characteristics and Sources of Mycobacterium Kansasii?
Mycobacterium kansasii is a rod-shaped, slowly developing kind of bacteria. Although it can grow at 37 degrees Celsius, it prefers to grow at about 32 degrees. In several aspects, it resembles other bacteria known as M. marinum and M. szulgai. Colonies take more than seven days to form when grown in a lab. Similar to other members of its family, M. kansasii is immobile, lacks spore formation, and is colorless. Its colonies can have a variety of shapes and sizes; they can be elevated, smooth, or rough.
It appears wider and longer under a microscope than tuberculosis bacteria. When stained and examined, it may look cross-barred or beaded. Its colonies are colorless when originally cultivated in the dark, but when exposed to light, a pigment known as beta-carotene causes them to turn yellow.
In the laboratory, scientists look for things like the presence of specific enzymes or chemical breakdown products to identify them. However, it may take a while to identify it precisely, up to two months.
Recent research has revealed at least seven distinct varieties of M. kansasii, despite the scientific community's previous belief that they all were the same. Subtype 1 is the most prevalent one in humans. These bacteria may be identical worldwide and have a very close relationship with one another.
Although M. kansasii is rarely found in soil, it is present in many other environmental settings. It can be found in various places, including fish bites, swimming pools, and tap water. It appears to reside primarily in tap water. Usually, breathing it in through the air is how people become infected. Except for a few instances where members of the same family have fallen ill, it is not particularly contagious. However, it is most likely a result of their common environment or comparable health issues rather than direct transmission.
Who Is Most Affected by M. Kansasii Infections?
M. kansasii infections typically affect men between the ages of 45 and 62. These illnesses frequently occur in certain locations in some regions of the United States, including Texas, Louisiana, Florida, Illinois, Kansas, and Nebraska. They may be related to mining because they are more prevalent in cities than rural areas.
M. kansasii infections are more common in locations with high HIV (human immunodeficiency virus) prevalence, such as in some parts of Africa, since HIV-positive individuals are more susceptible to contracting the illness.
In the 1960s and 1970s, M. kansasii was the most frequent non-tuberculosis infection; however, M. avium-intracellulare became the more common form of bacteria. But as HIV became widely distributed in the 1980s, M. kansasii infections became highly contagious again. However, with improved HIV therapies, these infections are currently declining in frequency once again.
Both individuals with strong and compromised immune systems may contract these infections. Approximately 0.5 out of every 100,000 individuals was thought to have these illnesses in the 1980s. Although their frequency in organ transplant recipients is unknown, they can spread throughout the body when they do. These infections mostly affect the lungs in HIV-positive individuals, though they can sometimes spread to other body areas.
What Are the Clinical Patterns and Manifestations of M. Kansasii Infections?
Mycobacterial infections, such as those brought on by M. kansasii, can affect different body sections and present diverse clinical patterns. The following are the primary ways that they may affect people:
-
Pulmonary Disease: Chronic pulmonary illness, which mostly affects the upper region of the lungs, is the most typical manifestation of M. kansasii infections. Particularly in older persons, this can frequently imitate tuberculosis, exhibiting symptoms such as coughing up blood, producing sputum, weight loss, dyspnea, chest pain, and, on occasion, fever or sweats.
-
Skin and Soft Tissues: Nodules, pustules, verrucous lesions, erythematous plaques, abscesses, or ulcers are just a few of the skin infections that M. kansasii can cause. These skin infections can be more severe in individuals with compromised immune systems, such as those living with HIV, and can result in consequences including cellulitis or osteomyelitis.
-
Infections of the Muscles: This comprises tenosynovitis and monoarticular septic arthritis, in which the bacteria infect the surrounding tissues or the joints. Bone involvement in disseminated M. kansasii illness is prevalent, including spinal osteomyelitis and sacroiliitis.
-
Disseminated Disease: When M. kansasii is severe, it can spread throughout the body and cause nonspecific symptoms such as lymphadenopathy (swollen lymph nodes), hepatosplenomegaly (enlarged spleen and liver), fever, and pulmonary infiltrates. Abscesses, liver granulomas, and bone marrow granulomas can also happen.
-
Catheter-Associated Disease: People with indwelling medical devices are more susceptible to catheter-related infections.
-
Lymphadenitis: Although less common than other symptoms, lymph node infections might occur.
Like other mycobacteria, smoking, lung conditions, cancer, compromised immune systems, renal issues, and history of tuberculosis infection are risk factors for M. kansasii infections.
Early detection and effective intervention are essential, particularly in light of the potential for progressive lung damage from untreated pulmonary infections. Furthermore, co-infection with M. kansasii can cause serious systemic disease in advanced HIV infections. For efficient therapy and avoiding problems, it is crucial to comprehend the various clinical manifestations of M. kansasii infections.
How Do Doctors Diagnose M. Kansasii Infection?
Doctors must do specialized tests to determine whether a patient has an M. kansasii infection because the infection's symptoms are nonspecific and might mimic those of other disorders. In these tests, samples of the subject, such as their sputum (the material patients cough up from the lungs), are used to cultivate the bacteria. When M. kansasii is detected in these samples, it typically indicates that the individual is truly ill and not merely transporting the bacterium from their surroundings.
Testing for M. kansasii can be done using accurate methods like PCR. However, the most accurate way to diagnose it is to grow it in a lab using samples taken from the patient.
To help diagnose M. kansasii, medical professionals also consider other data, such as the patient's symptoms and results from chest CT or X-ray scans. A diagnosis of M. kansasii infection typically entails observing specific features on imaging tests, obtaining positive cultures from sputum, and ruling out other potential infections, according to guidelines from medical organizations.
Typically, for the diagnosis to be confirmed, two distinct positive sputum cultures, one positive bronchoscopy sample, one positive culture, and lung disease symptoms. This ensures that the patient receives the appropriate care and accurate diagnosis.
How Is M. Kansasii Infection Treated and Monitored?
Rifampin is the primary medication used to treat M. kansasii infections. Doctors typically mix the medication with Isoniazid, Pyridoxine (vitamin B6), and Ethambutol to ensure its effectiveness. Until the patient's tests indicate that the germs have disappeared for at least a year, the treatment typically lasts a year or even longer.
Since Pyrazinamide typically does not work against M. kansasii bacteria, it is not used in treatment. Additionally, although initially, the bacteria may appear resistant to isoniazid, doctors have discovered that if the body has a greater-than-normal concentration of the drug, it can still be effective. Isoniazid can, therefore, still be useful even if the blood tests reveal low amounts.
Combinations of Rifampin and other drugs are generally effective in treating infections; failure or recurrence of the infection is rare.
To ensure that M. kansasii-infected HIV-positive individuals can take Rifampin correctly, clinicians may modify the patients' HIV medication. Physicians may substitute Rifabutin for Rifampin in select cases, particularly if the patient is on protease inhibitors or non-retroviral therapy (NNRTI).
Doctors periodically look for germs in the patient's sputum or the gunk they cough up, and they may also perform chest X-rays to ensure the treatment is having the desired effect. They also monitor the patient for any adverse drug reactions and determine whether the medications could interfere with other medications they are taking. This enables them to detect issues early and ensure that the treatment continues to be efficacious.
Conclusion
Mycobacterium kansasii infections, especially those affecting the lungs, can resemble tuberculosis and pose a serious health risk, particularly those with weakened immune systems. Its capacity to spread throughout the body, impacting different tissues and organs, emphasizes how crucial a proper diagnosis and prompt treatment are. The mainstay of treatment is still rifampin-based therapy, which is frequently used in conjunction with other antibiotics. Routine monitoring for medication efficacy and possible side effects is crucial to guarantee effective treatment of this infection and avoid long-term consequences.
